SecBot SecBot
8-K ·Filed Nov 6, 2026

RGEN

REPLIGEN CORP
NEUTRAL
Impact 4/10
Horizonweeks Processed10d 5h ago SEC0001628280-26-071650
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight • Neutral

The refinancing extends debt maturities and lowers interest costs while adding cash. Monitor the company's use of the $458.6M cash proceeds and any future conversion activity that could dilute equity. The remaining $143.2M of 2028 notes still outstanding could be addressed in a future transaction.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$178.94
T+0 close · Nov 6, 2026 · via day close
Latest settled
−9.03%
T+5 · $162.78
Vs SPY
−7.34%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $178.94entry
  2. T+1 · 7d ago −2.77%α −2.40% · $173.98
  3. T+5 · 14h ago −9.03%α −7.34% · $162.78
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Repligen issued $1.0 billion aggregate principal amount of 0.25% Convertible Senior Notes due 2031. Approximately $541.4 million of the new notes were exchanged for $456.8 million of existing 1.00% Convertible Senior Notes due 2028 (which were canceled), and approximately $458.6 million was issued for cash. The transaction reduces the company's interest expense, extends debt maturities, and adds cash to the balance sheet, but introduces potential dilution of up to 5.3 million shares upon conversion.

Key Financial Metrics

Offering Size
$1.0B

Key Facts

  • Issued $1.0 billion aggregate principal amount of 0.25% Convertible Senior Notes due 2031
  • Exchanged $541.4 million of new notes for $456.8 million of existing 1.00% Convertible Senior Notes due 2028, which were canceled
  • Issued $458.6 million of new notes for $458.6 million in cash
  • Remaining $143.2 million of 2028 Notes outstanding with terms unchanged
  • Initial conversion price of approximately $226.37 per share, representing a ~20% premium over the $188.64 closing price on October 29, 2026
  • Up to 5,301,100 shares of common stock may be issued upon conversion of the new notes
  • New notes mature November 1, 2031, pay 0.25% interest semi-annually
  • Company may redeem notes on or after November 6, 2029 if stock price is at least 130% of conversion price

Financial Impact

Reduced annual interest expense from ~$4.6M on the exchanged $456.8M of 1.00% notes to ~$1.4M on the $541.4M of new notes issued in exchange; net cash inflow of ~$458.6M; potential dilution of up to ~5.3M shares (approximately 3% of shares outstanding based on market cap of $11.4B and stock price of $188.64).

interest expensedebtcashdilution

Risk Factors

  • Potential dilution of up to 5.3 million shares if notes are converted
  • Remaining $143.2M of 2028 notes still outstanding with higher 1.00% coupon
  • Conversion premium of ~20% may limit near-term conversion activity

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-071650
Document: 0001628280-26-071650-index.html0001628280-26-071650
Document: 0001628280-26-071650.txt0001628280-26-071650

Track record

16 reports on RGEN

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +31.47% at T+60 after the Jul 22, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 6, 202610d ago 8-K Neutral 4/10 Viewing Entry $178.94 Now $167.79 −6.23% settles Feb 5
  2. Oct 30, 202617d ago 8-K Neutral 5/10 Entry $176.94 Now $167.79 −5.17% settles Jan 28
  3. Oct 27, 202620d ago 8-K Bullish 6/10 No price data
  4. Oct 27, 202620d ago Press Release Bullish 6/10 Entry $175.80 Now $167.79 −4.56% settles Jan 25
  5. Oct 15, 20264w ago Institutional Cluster Mixed 3/10 Entry $184.17 Now $167.79 −8.89% settles Jan 12
  6. Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $167.22 Now $167.79 +0.34% settles Jan 4
  7. Oct 6, 20265w ago 8-K Bullish 6/10 Entry $174.86 Now $167.79 −4.04% settles Dec 31
  8. Oct 6, 20265w ago Press Release Bullish 6/10 Entry $174.86 Now $167.79 −4.04% settles Dec 31
  9. Aug 24, 202612w ago S-4 Neutral 6/10 Entry $181.69 Now $167.79 −7.65% settles Nov 18
  10. Jul 28, 202615w ago 8-K Bullish 7/10 Entry $145.34 to $180.01 Now $167.79 +15.45% ▲ +23.85% +19.50% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens Wed (12h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026